Voyager Acquisition's 10-K Details $270M Trust, Confirms Veraxa Biotech Merger Path
Summary
Voyager Acquisition Corp. filed its annual 10-K report, detailing nominal revenues of $0.011 million and $0.28 EPS, primarily derived from investment income within its trust account. The company reported a net income of $8.989 million. As a blank-check company (SPAC), these figures are typical, reflecting investment income rather than operational performance. The filing confirms that the SPAC holds approximately $269.9 million in its trust account and reiterates its ongoing business combination agreement with Veraxa Biotech. This formal financial update provides critical context following recent news of VERAXA Biotech AG shareholders approving the merger. Investors will continue to monitor the progress of the Veraxa Biotech merger as the mandatory liquidation date of August 12, 2026, approaches.
At the time of this announcement, VACH was trading at $10.63 on NASDAQ in the Finance sector, with a market capitalization of approximately $336.2M. The 52-week trading range was $10.06 to $10.99. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.